Albuterol sulfate inhalation solution (ProAir HFA) has won FDA approval for use in asthmatic children. Side effects resembled those found in adult and adolescent trials.

Users of inhaled anticholinergic agents for COPD showed a 58% increases in risk of cardiovascular death, heart attack, or stroke, versus users of placebos or other inhaled COPD drugs.

Healthcare professionals should avoid using greater-than or less-than symbols when writing notes about medication, because it increases the risk of error, according to the Institute for Safe Medical Practices.

Recent research favors use of telmisartan (Micardis) for treating vascular disease and high-risk diabetes in those who can't take angiotensin-converting enzyme inhibitors, according to a study published in The Lancet.

The FDA has approved use of tetrabenazine (Xenazine) for treatment of chorea symptoms in Huntington's disease sufferers.

Erythropoiesis-stimulating agents Aranesp and Epogen must display a revised box warning and a new restricted indication to comply with FDA findings about their use for cancer patients receiving myelosuppressive therapy.

A British study has noted a rise in birth defects in a 178-subject sample of children exposed to epilepsy drug topiramate (Topamax) in utero.

Dizziness and blurred vision in a 63-year-old patient can be traced to use of BiDil, a combination therapy given for the patient's hypertension and congestive heart failure.

The FDA has mandated black-box warnings for fluoroquinolone antibiotics to alert clinicans to increased risk of tendonitis and tendon rupture.